SAI-TGF-alpha

Drug Profile

SAI-TGF-alpha

Alternative Names: Cancer vaccine TGF-alpha - Micromet; TGF-alpha cancer vaccine - Micromet

Latest Information Update: 29 Mar 2012

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Center of Molecular Immunology
  • Developer Amgen; Center of Molecular Immunology
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 07 Mar 2012 Micromet Inc has been acquired by Amgen
  • 02 Mar 2012 No development reported - Preclinical for Cancer in North America (unspecified route)
  • 13 Aug 2009 SAI-TGF-alpha is available for licensing or purchase (http://www.micromet.de)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top